Introduction Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes (T2DM), with a relevant impact on the economic costs for health care systems and on the quality of life for many patients ( Among the novel therapies, great interest has been aroused by sodiumglucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), that have changed the management of diabetic patients
Tendo-se em vista o papel das -glicosidases na digesto de acares, inibidores destas enzimas so atualmente empregados no tratamento do diabetes mellitus tipo II, proporcionando um controle da hiperglicemia ps-prandial, atravs da modulao da taxa de digesto do amido e outros carboidratos complexos (ALVES DA CONCEIO et al., 2017)
Patients should seek prompt medical guidance for severe or persistent vomiting, signs of dehydration, severe abdominal pain, fainting, symptoms of low blood sugar, inability to keep fluids down, worsening constipation with pain or bloating, or any symptom that feels unsafe
While the brother experienced a reduction in BMI, his body weight and body fat percentage continued to increase, demonstrating different therapeutic responses compared to the previously reported cases
17 With regard to dapagliflozin, it is now established that the cardiac benefits are the same for both people with and without diabetes
We did not evaluate small-study effect bias with a funnel plot due to the small number of included trials [16]
